Patents by Inventor David Klatzmann

David Klatzmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOW DOSE IL-2 FOR TREATING AUTOIMMUNE-RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20230149512
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: January 6, 2023
    Publication date: May 18, 2023
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David KLATZMANN, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • Genetically modified T lymphocytes
    Patent number: 11648271
    Abstract: The invention relates to a composition comprising regulatory T (Treg) cells or effector T cells (Teff) which stably express an interleukin selected from the group consisting of interleukin-2 (IL-2) or interleukin-15 (IL-15).
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: May 16, 2023
    Inventor: David Klatzmann
  • INTERLEUKIN 2 CHIMERIC CONSTRUCTS
    Publication number: 20230036793
    Abstract: The present invention relates to a chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a beta chain of the C4b-binding protein (C4BP?) or at least one fragment or functional variant thereof that is capable of forming a dimeric protein.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Inventors: David KLATZMANN, Nicolas BILLIALD, Thomas VAZQUEZ, Jérémie MARIAU
  • Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders
    Patent number: 11559566
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: January 24, 2023
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Use of interleukin 2 for treating Sjögren's syndrome
    Patent number: 11534479
    Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: December 27, 2022
    Assignees: ILTOO PHARMA, ASSISTANCE PUBLIQUE—HÖPITAUX DE PARIS, SORBONNE UNIVERSITÉ
    Inventors: David Klatzmann, Roberta Lorenzon, Michèle Rosenzwajg, Patrice Cacoub, Arsene Mekinian
  • Virus-like particles which can be used in the treatment of autoimmune diseases
    Patent number: 11306294
    Abstract: The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 19, 2022
    Assignees: Sorbonne Universite, INSERM (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique—Hopitaux De Paris
    Inventors: Bertrand Bellier, David Klatzmann
  • Compositions and methods for treatment of cytomegalovirus
    Patent number: 11248026
    Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: February 15, 2022
    Assignees: Variation Biotechnologies Inc., Sorbonne Université
    Inventors: David E. Anderson, Anne-Catherine Fluckiger, David Klatzmann, Charlotte Dalba-Fribert
  • VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIES
    Publication number: 20210299195
    Abstract: The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy.
    Type: Application
    Filed: October 28, 2018
    Publication date: September 30, 2021
    Inventors: Bertrand Bellier, David Klatzmann
  • COMBINATION OF INTERLEUKIN-2 WITH AN INTERLEUKIN 1 INHIBITOR, CONJUGATES AND THERAPEUTIC USES THEREOF
    Publication number: 20210236599
    Abstract: The present invention relates to a combination of i) interleukin-2 (IL-2) and ii) an interleukin 1 (IL-1) inhibitor, for use in treating an auto-immune and/or inflammatory disorder in a subject. It is also provided a pharmaceutical composition comprising interleukin-2 (IL-2) and an interleukin-1 (IL-1) inhibitor. The invention further provides a conjugate comprising IL-2 conjugated to an IL-1 inhibitor.
    Type: Application
    Filed: August 13, 2019
    Publication date: August 5, 2021
    Inventors: David Klatzmann, Jérémie Mariau, Paul-Gydéon Ritvo, Encarnita Mariotti-Ferrandiz, Thomas Vazquez, Nicolas Billiald
  • USE OF INTERLEUKIN 2 FOR TREATING SJÖGREN'S SYNDROME
    Publication number: 20210121532
    Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
    Type: Application
    Filed: February 18, 2019
    Publication date: April 29, 2021
    Applicants: ILTOO PHARMA, ASSISTANCE PUBLIQUE - HÖPITAUX DE PARIS, SORBONNE UNIVERSITÉ
    Inventors: David KLATZMANN, Roberta LORENZON, Michèle ROSENZWAJG, Patrice CACOUB, Arsene MEKINIAN
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE-RELATED OR INFLAMMATORY
    Publication number: 20210038691
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20200347363
    Abstract: The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.
    Type: Application
    Filed: October 26, 2018
    Publication date: November 5, 2020
    Inventors: Bertrand Bellier, David Klatzmann
  • Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
    Patent number: 10765723
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 8, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE - RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20190351023
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: March 22, 2019
    Publication date: November 21, 2019
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Interleukin-2 for treating food allergy
    Patent number: 10376564
    Abstract: The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol in combination with a food allergen.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 13, 2019
    Assignees: SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Klatzmann, Bertrand Bellier
  • GENETICALLY MODIFIED T LYMPHOCYTES
    Publication number: 20190151364
    Abstract: The invention relates to a composition comprising regulatory T (Treg) cells or effector T cells (Teff) which stably express an interleukin selected from the group consisting of interleukin-2 (IL-2) or interleukin-15 (IL-15).
    Type: Application
    Filed: June 22, 2017
    Publication date: May 23, 2019
    Inventor: David KLATZMANN
  • Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
    Patent number: 10293028
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 21, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michéle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • USE OF INTERLEUKIN 2 FOR TREATING SPONDYLOARTHRITIS
    Publication number: 20190060407
    Abstract: The invention relates to the use of interleukin-2 in treating spondyloarthritis in a human subject, wherein IL-2 is to be administered at a dose of about I to about 2 MIU/day, wherein the treatment comprises at least a first course wherein interleukin-2 is administered once per day during at least 3 consecutive days, followed by a maintenance treatment after 1 to 4 weeks.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 28, 2019
    Applicants: Assistance Publique - Hôpitaux De Paris, ILTOO PHARMA, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, Francis Berenbaum, Jérémie Sellam, Bruno Fautrel, Roberta Lorenzon, Patrice Cacoub
  • PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY
    Publication number: 20180228913
    Abstract: The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.
    Type: Application
    Filed: August 9, 2017
    Publication date: August 16, 2018
    Inventors: David KLATZMANN, Eliane PIAGGIO, Hugo LUJAN
  • Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
    Patent number: 9801927
    Abstract: The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 31, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSITANCE PUBLIQUE HOPITAUX DE PARIS, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), UNIVERSIDAD CATOLICA DE CORCOBA (UCC)
    Inventors: David Klatzmann, Eliane Piaggio, Hugo Daniel Luján